Patents Examined by Dennis Heyer
  • Patent number: 11324789
    Abstract: A method of treating equine encephalitis is provided. A composition having at least one cardiac glycoside, such as oleandrin, is used to treat a viral infection causing the encephalitis. The composition can further include at least one triterpene. Alternatively, the composition comprises at least one, at least two, or at least three triterpenes.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: May 10, 2022
    Assignee: PHOENIX BIOTECHNOLOGY, INC.
    Inventors: Robert A. Newman, Otis C. Addington
  • Patent number: 11312709
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: April 26, 2022
    Assignee: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Anish Bandyopadhyay, Mui Cheung, Hilary Schenck Eidam, Hemant Joshi, Dai-Shi Su
  • Patent number: 11305017
    Abstract: The invention described herein relates to methods and compositions for treating cancer in a patient or a tumor cell by administering an effective amount of an anti-fugetactic agent and an additional anti-cancer agent.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: April 19, 2022
    Assignee: The General Hospital Corporation
    Inventors: Mark C. Poznansky, Patrick Reeves
  • Patent number: 11299497
    Abstract: The present invention relates to novel substituted tetrahydropyran dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 12, 2022
    Assignee: UNION therapeutics A/S
    Inventors: Jens Larsen, Simon Feldbaek Nielsen, Peter Andersen
  • Patent number: 11292799
    Abstract: The present invention relates to novel substituted azetidine dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 5, 2022
    Assignee: UNION THERAPEUTICS A/S
    Inventors: Mark Andrews, Daniel Rodriguez Greve, Jens Larsen
  • Patent number: 11285101
    Abstract: A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: March 29, 2022
    Assignee: Intervet Inc.
    Inventors: Susi Alteheld, Stefan Fuchs, Carina Hang, J├╝rgen Lutz
  • Patent number: 11286268
    Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 29, 2022
    Assignee: eFFECTOR Therapeutics, Inc.
    Inventors: Samuel Sperry, Alan X. Xiang, Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Mike Shaghafi, Theo Michels, Christian Nilewski, Chinh Viet Tran, Garrick Kenneth Packard, Alan Grubbs, Kaveri Urkalan, Takasuke Mukaiyama
  • Patent number: 11285151
    Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: March 29, 2022
    Assignee: EMORY UNIVERSITY
    Inventors: Michael G. Natchus, Richard Arrendale, Dennis Liotta, Ketan Desai, Hyunsuk Shim
  • Patent number: 11285213
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: March 29, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11285214
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: March 29, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11248002
    Abstract: Disclosed are a sesquiterpene derivative and a use of the same in preparation of a medicament for treating hepatitis B diseases. The sesquiterpene derivative has the effects of down-regulating the hepatocyte nuclear factor 4? (HNF-4?) and significantly inhibiting the hepatitis B virus, and can be used for preventing and/or treating and/or assisting in the treatment of liver system diseases and symptoms caused by the hepatitis B virus, and can be used as a hepatic protective agent. In addition, the synthetic sesquiterpene derivative can also be used for preventing or treating viral infectious diseases and conditions resulting from the influenza virus, coxsackievirus, herpes simplex virus, etc. Also involved is the preparation of the synthetic sesquiterpene derivative, which acts as a raw material, in clinically acceptable pharmaceutical formulations, such as oral dosage forms such as tablets, capsules and drop pills or non-oral dosage forms such as inhalants and injections.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: February 15, 2022
    Assignee: KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Min Xu, Haoyang Yuan, Haizhou Li, Yingjun Zhang, Chongren Yang
  • Patent number: 11234973
    Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: February 1, 2022
    Assignees: PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, Agency for Science, Technology and Research
    Inventors: Michael Hayden, Mahmoud Abdulhossein Pouladi
  • Patent number: 11230547
    Abstract: The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth A. McGowan, Jason D. Katz, Matthew Christopher, Hua Zhou, David James Witter, Chaomin Li, John Lampe, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu
  • Patent number: 11229635
    Abstract: The present disclosure is directed to method of treatment for treating or ameliorating various conditions pertaining such as bone marrow recovery (or blood cell production), fibrosis, inflammatory diseases, inhibition of cancer cell growth, propagation or malignancy, thrombocytopenia, wound healing, and conditions related to stem cells by the administration of BCN057, 512, or an analog thereof.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: January 25, 2022
    Assignee: BCN Biosciences L.L.C.
    Inventor: Andrew J. Norris
  • Patent number: 11219624
    Abstract: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: January 11, 2022
    Assignee: INCYTE HOLDINGS CORPORATION
    Inventors: Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
  • Patent number: 11213509
    Abstract: The present invention relates, in certain embodiments, to methods for preventing and/or treating neurodegenerative damage (e.g., secondary cascade of neurodegenerative damage) and improving functional outcomes (e.g., outcomes associated with cognitive, behavior and sensorimotor function) caused by traumatic brain injury using neuroprotective lipoyl compounds. The present invention also provides, in various embodiments, compositions for use in treating and/or preventing TBI in a subject in need thereof, compounds for use in the manufacture of a medicament for treating and/or preventing TBI in a subject in need thereof, and methods of preparing a pharmaceutical composition for treating and/or preventing secondary brain damage caused by TBI.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: January 4, 2022
    Assignee: ISCHEMIX, LLC
    Inventors: Alexander Baguisi, Reinier Beeuwkes, Ralph Casale, David A. DeWahl, Jr., Steven A. Kates, Alan S. Lader
  • Patent number: 11214536
    Abstract: The present invention relates to new polymorphs of LXR? agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXR? agonist, as well as methods of treating cancer including administration of a formulation including an LXR? agonist to a subject in need thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: January 4, 2022
    Assignee: Inspirna, Inc.
    Inventors: Saurabh Chitre, Hayley Reece, Stephen Wald
  • Patent number: 11213587
    Abstract: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: January 4, 2022
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Arturo Angel, Gordon Dow
  • Patent number: 11191761
    Abstract: Disclosed is an SOMCL-9112 solid dispersion. The SOMCL-9112 solid dispersion is characterized by being prepared from the following raw materials in percentage by weight: 5 percent to 60 percent of SOMCL-9112, 5 percent to 90 percent of pharmaceutically acceptable matrix polymer, 0 percent to 20 percent of surfactant, 0 percent to 20 percent of flow aid and 0 percent to 20 percent of plasticizer. Also disclosed are a preparation method of the SOMCL-9112 solid dispersion, a solid medicinal preparation containing the solid dispersion and application of the solid dispersion for preparing a medicine for treating cancer.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: December 7, 2021
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD.
    Inventors: Shiyan Guo, Yong Gan, Ao Zhang, Zehong Miao, Li Gao, Jian Ding
  • Patent number: 11191753
    Abstract: The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: December 7, 2021
    Assignee: FERRING INTERNATIONAL CENTER SA.
    Inventors: Bong Gil Nam, Byeung Jun Lee, Shunji Jin